1 jun 2018 ano - FDA sent safety labeling change notification letters to drug companies with approved opioid analgesic products intended for use in an outpatient setting, which require the companies to include new safety information regarding the Opioid Analgesic REMS in the Boxed Warning and Warnings and Precautions sections of prescribing information due to a general lack of awareness of the REMS among all opioid analgesic prescribers.

Adicionado na linha do tempo:

Opioids and the FDA

ByAnastasia

13 nov 2018

0 0 333

Data: